CIRP and Cathepsin B in Neuroinflammation After Intracerebral Hemorrhage
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXuanwu Hospital, Beijing
About this trial
This is a single-center, investigator-initiated, prospective observational case-control study. Patients with intracerebral hemorrhage and healthy controls will be enrolled at Xuanwu Hospital, Capital Medical University. Peripheral venous blood samples will be collected for measurement of CIRP, Cathepsin B, and related inflammatory biomarkers. Clinical and imaging data will also be collected in the intracerebral hemorrhage group. The study aims to compare biomarker levels between patients with intracerebral hemorrhage and healthy controls and to explore the potential role of these biomarkers in neuroinflammation after intracerebral hemorrhage. No investigational treatment will be administered.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Adults with intracerebral hemorrhage admitted to Xuanwu Hospital, Capital Medical University, and age-eligible healthy controls recruited from the hospital health examination center. The intracerebral hemorrhage group includes patients with supratentorial, non-surgical intracerebral hemorrhage confirmed by CT or MRI and admitted within 24 hours after symptom onset. The healthy control group includes adults without stroke or other major neurological diseases.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Blood Sample Collection
Other interventionPeripheral venous blood sample collection for biomarker measurement only; no investigational treatment is administered.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Intracerebral Hemorrhage Group1 intervention
Group B: Healthy Control Group1 intervention
Trial outcomes
Primary outcomes
1
Peripheral Blood CIRP Level
Comparison of peripheral blood CIRP levels between the intracerebral hemorrhage group and the healthy control group.
Time frame
Within 24 hours after enrollment for the intracerebral hemorrhage group; once at baseline on the day of blood collection for healthy controls.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: